Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications

被引:17
作者
Li, Yijia [1 ,2 ]
Wu, Yangzhe [1 ,2 ]
Hu, Yi [3 ]
机构
[1] Jinan Univ, Zhuhai Hosp, Zhuhai Peoples Hosp, Zhuhai Inst Translat Med, Zhuhai, Peoples R China
[2] Jinan Univ, Biomed Translat Res Inst, Guangzhou, Peoples R China
[3] Jinan Univ, Sch Med, Microbiol & Immunol Dept, Guangzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
基金
中国国家自然科学基金;
关键词
tumor microenvironment; metabolites; immune cell reprogramming; epigenetic modifications; anti-tumor immunity; T-CELL; DNA METHYLATION; HISTONE ACETYLATION; CANCER; RECEPTOR; THERAPY; CHECKPOINTS; MECHANISMS; REGULATORS; LANDSCAPE;
D O I
10.3389/fimmu.2021.641883
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cellular metabolism of both cancer and immune cells in the acidic, hypoxic, and nutrient-depleted tumor microenvironment (TME) has attracted increasing attention in recent years. Accumulating evidence has shown that cancer cells in TME could outcompete immune cells for nutrients and at the same time, producing inhibitory products that suppress immune effector cell functions. Recent progress revealed that metabolites in the TME could dysregulate gene expression patterns in the differentiation, proliferation, and activation of immune effector cells by interfering with the epigenetic programs and signal transduction networks. Nevertheless, encouraging studies indicated that metabolic plasticity and heterogeneity between cancer and immune effector cells could provide us the opportunity to discover and target the metabolic vulnerabilities of cancer cells while potentiating the anti-tumor functions of immune effector cells. In this review, we will discuss the metabolic impacts on the immune effector cells in TME and explore the therapeutic opportunities for metabolically enhanced immunotherapy.
引用
收藏
页数:10
相关论文
共 149 条
  • [1] Epigenetic therapy in gastrointestinal cancer: the right combination
    Abdelfatah, Eihab
    Kerner, Zachary
    Nanda, Nainika
    Ahuja, Nita
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (04) : 560 - 579
  • [2] KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer
    Alam, Hunain
    Tang, Ming
    Maitituoheti, Mayinuer
    Dhar, Shilpa S.
    Kumar, Manish
    Han, Chae Young
    Ambati, Chandrashekar R.
    Amin, Samir B.
    Gu, Bingnan
    Chen, Tsai-Yu
    Lin, Yu-Hsi
    Chen, Jichao
    Muller, Florian L.
    Putluri, Nagireddy
    Flores, Elsa R.
    DeMayo, Francesco J.
    Baseler, Laura
    Rai, Kunal
    Lee, Min Gyu
    [J]. CANCER CELL, 2020, 37 (04) : 599 - +
  • [3] Regulatory T Cell Stability and Plasticity in Atherosclerosis
    Ali, Aural J.
    Makings, Jeffrey
    Ley, Klaus
    [J]. CELLS, 2020, 9 (12)
  • [4] Allogenic V9V2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
    Alnaggar, Mohammed
    Xu, Yan
    Li, Jingxia
    He, Junyi
    Chen, Jibing
    Li, Man
    Wu, Qingling
    Lin, Li
    Liang, Yingqing
    Wang, Xiaohua
    Li, Jiawei
    Hu, Yi
    Chen, Yan
    Xu, Kecheng
    Wu, Yangzhe
    Yin, Zhinan
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [5] Epigenetic control of myeloid cell differentiation, identity and function
    Alvarez-Errico, Damiana
    Vento-Tormo, Roser
    Sieweke, Michael
    Ballestar, Esteban
    [J]. NATURE REVIEWS IMMUNOLOGY, 2015, 15 (01) : 7 - 17
  • [6] Leucine Metabolism in T Cell Activation: mTOR Signaling and Beyond
    Ananieva, Elitsa A.
    Powell, Jonathan D.
    Hutson, Susan M.
    [J]. ADVANCES IN NUTRITION, 2016, 7 (04) : 798S - 805S
  • [7] Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
    Anderson, Kristin G.
    Stromnes, Ingunn M.
    Greenberg, Philip D.
    [J]. CANCER CELL, 2017, 31 (03) : 311 - 325
  • [8] Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments
    Angelin, Alessia
    Gil-de-Gomez, Luis
    Dahiya, Satinder
    Jiao, Jing
    Guo, Lili
    Levine, Matthew H.
    Wang, Zhonglin
    Quinn, William J., III
    Kopinski, Piotr K.
    Wang, Liqing
    Akimova, Tatiana
    Liu, Yujie
    Bhatti, Tricia R.
    Han, Rongxiang
    Laskin, Benjamin L.
    Baur, Joseph A.
    Blair, Ian A.
    Wallace, Douglas C.
    Hancock, Wayne W.
    Beier, Ulf H.
    [J]. CELL METABOLISM, 2017, 25 (06) : 1282 - +
  • [9] Epigenetic modifiers as new immunomodulatory therapies in solid tumours
    Aspeslagh, S.
    Morel, D.
    Soria, J. -C.
    Postel-Vinay, S.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (04) : 812 - 824
  • [10] Histone Modifications and Cancer
    Audia, James E.
    Campbell, Robert M.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2016, 8 (04):